Immix Biopharma Inc (IMMX)

[subslover]

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
December 12 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed release testing and shipped Good Manufacturing Practice (“GMP”) process manufactured batches of IMX-110 for clinical trial patient dosing. IMX-110 was produced using our proprietary, scaled-up manufacturing process that will provide drug supply for 2 clinical trials: IMX-110 monotherapy and combination IMX-110 + BeiGene/Novartis anti-PD-1 tislelizumab clinical trial in advanced solid tumors.
“Completing release testing and shipping GMP IMX-110 manufactured with our new scaled-up, proprietary process for patient dosing is a pivotal milestone,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “We are looking forward to releasing clinical data in our IMX-110 monotherapy and IMX-110 plus BeiGene/Novartis anti-PD-1 tislelizumab combination clinical trial.”

About IMX-110